Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea · Delayed Price · Currency is KRW 9,490.00
-390.00 (-3.95%)
At close: Feb 6, 2026
Vaxcell-Bio Therapeutics Revenue
In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.
Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
220.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 1.89B | 13,737.28% |
| Dec 31, 2023 | 13.72M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 66.39B |
| Genome & Company | 25.95B |
| Prestige Biologics | 13.36B |
| QuadMedicine | 13.11B |
| Kangstem Biotech | 12.77B |
| TiumBio | 9.32B |
| Bio Solution | 8.27B |
| curacle co.,ltd. | 1.14B |